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Abstract
Background: Frailty is an aggregate expression of susceptibility to poor outcomes, owing to age-, and disease-
related deficits that accumulate within multiple domains. Older patients who are frail before surgery are at an
increased risk of morbidity and mortality, and use a disproportionately high amount of healthcare resources. While
frailty is now a well-established risk factor for adverse postoperative outcomes, the perioperative literature lacks
studies that: 1) compare the predictive accuracy of different frailty instruments; 2) consider the impact of frailty on
patient-reported outcome measures; and 3) consider the acceptability and feasibility of using frailty instruments in
clinical practice.
Methods: We will conduct a multicenter prospective cohort study comparing the predictive accuracy of the
modified Fried Index (mFI) with the Clinical Frailty Scale (CFS) among consenting patients aged 65 years and older
having elective major non-cardiac surgery. The primary outcome will be disability free survival at 90 days after
surgery, a patient-reported outcome measure. Secondary outcomes will include complications, length of stay,
discharge disposition, readmission and total health system costs. We will compare the accuracy of frailty
instruments using the relative true positive rate and relative false positive rate. These measures can be interpreted
as the relative difference in the probability of one instrument identifying a true case of death or new disability
compared to another instrument, or the relative difference in the probability of one instrument identifying a false
case of death or new disability, respectively. We will also assess the acceptability and feasibility of each instrument.
Discussion: Frailty is an important prognostic factor in the growing population of older patients having surgery.
This study will provide novel findings regarding the choice of an accurate, clinically useable frailty instrument in
predicting patient reported outcomes, as well as morbidity, mortality and resource use. These findings will inform
current practice and future research.
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Background
Frailty is an aggregate expression of susceptibility to
poor outcomes, that is due to age-related and
disease-related deficits [1] which accumulate within
physical, physiological, cognitive, and psychosocial
domains [2]. Frailty-related risk is manifest through
a vulnerability to stressors [3] that translates into in-
creased risk of mortality and adverse health out-
comes compared to non-frail individuals [2, 4, 5].
The prevalence of frailty increases exponentially with
age; [6] approximately 10% of 65–75 year olds are
frail while over 40% of individuals over 80 years of
age are frail [5].
Patients 65 years of age and older comprise an ever-
increasing proportion of the surgical population [7]. On
its own, advanced age is an important predictor of ad-
verse post-operative outcomes [8–10]. However, marked
variations in outcomes exist between surgical patients of
the same age [11]. Given the significant physiological
stress induced by surgery, it is not surprising that frailty
is a key factor explaining this variation. Frailty independ-
ently predicts mortality, morbidity, extended length of
stay, and institutional discharge after surgery [12–18].
Identifying frail patients prior to surgery could improve
the care and outcomes of older patients through a variety
of mechanisms: identification of high risk patients can
lead to improved decision making and informed proced-
ural consent [19], while the multidimensional nature of
frailty means that one or more of its underlying compo-
nents may be amenable to optimization at the patient-
level [20]. Furthermore, frail patients may benefit from
optimization of the healthcare system, such as
centralization of care.
Numerous frailty instruments exist to identify or diag-
nose individuals as frail [21]. Although different instru-
ments identify closely related high-risk groups of
patients, instruments are known to vary in their content
validity, feasibility, and ability to predict adverse health
outcomes [4]. To date, many different frailty instruments
have been used to identify high-risk patients in the acute
care setting [22]. However, few studies have compared
the performance of different frailty instruments in iden-
tifying high-risk frail older patients having surgery. Fur-
thermore, the majority of published studies describe the
association of frailty with routinely measured postopera-
tive outcomes, such as in-hospital or 30-day mortality,
complications, and length of stay (LOS) [22]. While
these outcomes provide important information for pa-
tients, clinicians and other stakeholders, the impact of
frailty on postoperative patient-reported outcome mea-
sures (PROMs) is poorly described [22]. The association
of preoperative frailty with postoperative PROMs is
clearly needed to provide more patient-centered insights
into the epidemiology of perioperative frailty.
Finally, despite recent recommendations from a variety
of national speciality societies that frailty be a routine
part of preoperative assessment in older patients [23,
24], there is currently no evidence that this recommen-
dation is consistently applied. In addition to a lack of
guidance regarding which frailty instrument to use in
the perioperative setting, there is a lack of knowledge re-
garding the acceptability and feasibility of different frailty
instruments in perioperative practice.
Based on the knowledge gaps described above, the ob-
jectives of this prospective cohort study are to 1) com-
pare the accuracy of the modified Fried Index [1] (mFI)
and the Clinical Frailty Scale [2] (CFS) in predicting dis-
ability free survival after elective non-cardiac surgery, 2)
compare their acceptability and feasibility in clinical
practice, and 3) explore the impact of adding other vari-
ables from guideline-recommended preoperative geriat-
ric assessment to the discriminatory performance of
frailty measures to predict disability free survival (DFS).
Methods
Study design and setting
We will conduct a prospective, multi-center cohort
study at a multi-site academic health sciences center
(The Ottawa Hospital (TOH)), and a community-
practice focussed single site hospital (Hôpital Montfort).
TOH is a 900-bed tertiary care center that is the re-
gional referral center for trauma, vascular, neuro, thor-
acic and complex oncology surgery, and serves a
catchment population of 1.2 million people. Hôpital
Montfort is a 300-bed hospital with a community-
focussed practice and serves a predominantly French-
speaking population. Both hospitals are located in
Ottawa, Canada. All patients will be recruited in the pre-
operative assessment unit of each hospital, where pa-
tients are seen by a registered nurse or physician
anesthesiologist for medical assessment prior to surgery.
Research ethics board (REB) approval has been granted
by each study center.
Study population
Individuals aged 65 years or older on the day of their
elective, major non-cardiac surgery will be eligible to
participate. Major non-cardiac surgery will be defined
as surgery not involving the heart, pericardium, or
cardiopulmonary bypass with an expected length of
stay of at least 2 days, and will be limited to primary
procedures (i.e., revisions of previous surgical proce-
dures will not be included).
Inclusion and exclusion criteria
All consenting patients having an eligible procedure who
are able to communicate in English or French, and who
are able to be contacted by telephone for follow up will
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be included. Because some frail patients may be cogni-
tively impaired, REB approval includes the ability for in-
formed study consent from a patient’s health decision
maker. However, patients unable to answer outcome
scales will be excluded. No other specific exclusion cri-
teria will be applied.
Primary independent variables
Our primary exposure of interest is the presence and se-
verity of frailty as measured by two existing frailty in-
struments with evidence of predictive utility and
feasibility in the acute care setting. The mFI [1] is a 5-
point frailty instrument based on a frailty phenotype
model which consists of measures of weight loss, grip
strength, exhaustion, walking speed, and activity level.
This instrument has been shown to predict adverse
events and institutional discharge after surgery with
moderate discrimination, and has been independently
tested in several surgical populations [25, 26]. The mFI
is currently recommended by the ACS/AGS best prac-
tice guidelines for frailty assessment before surgery [23].
The CFS is a 9-point global frailty scale based on clinical
evaluation in the domains of mobility, energy, physical
activity and function [2]. Despite its relative simplicity
and ease of use, the CFS is equally discriminative in pre-
dicting mortality compared to frailty indices containing
40+ variables [4, 27]. Additionally, the CFS may be more
feasible for clinical use than other frailty instruments
based on a smaller number of missing responses [4]. In
the acute care setting, increasing scores on the CFS are
associated with increasing risk of in-hospital mortality
[28–30]. All frailty assessments will be carried out by a
study clinician or one of three trained clinical research
assistants (CRA) during each patient’s preoperative as-
sessment unit visit. These visits typically occur 1–4
weeks prior to surgery. Assessments performed by CRAs
will be reviewed by a study clinician to ensure accuracy.
Frailty will be defined by typically used cut-offs for the
mFI (≥3) and CFS (≥4), however, various alternative
forms that account for the degree of frailty will also be
tested (see Analysis section).
Outcomes
The primary outcome will be disability free survival
(DFS) at 90 days after surgery, measured as a binary in-
dicator of being alive with a disability score of 25% or
less, based on the 12-item World Health Organization
Disability Assessment Schedule 2.0 (WHODAS) [31].
For people with a baseline WHODAS higher than 25%,
DFS will be defined as alive with a disability level of no
more than 8% above baseline [32]. The WHODAS will
be administered by telephone by a CRA blinded to the
participant’s preoperative frailty status. Previous studies
confirm the performance and applicability of the
WHODAS in a variety of disease states, including stroke
[33], spinal cord injury [34], trauma [35], chronic disease
states [36], and after surgery [32]. In addition to 90-day
measurement, we will also assess DFS at 30 and 365 days
after surgery. A 90-day primary outcome ascertainment
point was chosen for two reasons. First, outcomes be-
yond the traditional 30-day window are increasingly seen
as high-value metrics for patients [37], and second, the
WHODAS assesses disability in the 30 days prior to
questionnaire administration. Therefore, a 30-day post-
operative WHODAS score may be highly influenced by
the initial surgical insult, as opposed to each patient’s
longer-term functional trajectory.
Secondary outcomes will include complications (de-
fined by Post-Operative Morbidity Survey [38] criteria,
applied through a post-discharge chart review), patient
safety events (defined by International Classification of
Diseases Tenth Edition codes grouped by patient safety
indicator clusters using Type 2 diagnoses [39]), hospital
LOS, total health system costs (using standard person-
level cost algorithms to identify costs of the index
hospitalization, and total costs up to 30, 90 and 365 days
after surgery [40]), discharge disposition (home vs. sup-
ported or institutional discharge). All secondary out-
comes other than complications will be ascertained
using validated methods through linkage to provincial
health administrative data.
Covariates
Baseline clinical and demographic characteristics col-
lected will include data reported by patients or personal
support members/caregivers: age, gender, cognitive sta-
tus (using the AD8 questionnaire [41]), depression (Pa-
tient Health Questionnaire-2 screener [42]), alcohol
abuse (CAGE questionnaire [43]), self reported Elixhau-
ser comorbidities [44], current smoking status, presence
of hearing or visual deficits, recent unexpected weight
loss, history of falls in the previous 12 months, ability to
independently mobilize, dress, prepare meals, shop and
take care of finances. Additionally, we will capture co-
variates from health administrative data: American Soci-
ety of Anesthesiologists score, laboratory data ordered in
the preoperative assessment unit, number of prescription
medications, use of high-risk medications (opioids, ben-
zodiazepines, anti-histamines, other anti-cholinergic
drugs), anesthesia type, duration of surgery, surgery type
(as defined by the first 5 digits of the Canadian Classifi-
cation of Interventions code), and surgical risk (as de-
fined by the Procedural Index for Mortality Risk [45]).
Pertinent covariates were identified from existing pre-
operative risk prediction tools, as well as the ACS/AGS
Optimal Preoperative Assessment of the Geriatric Sur-
gery Patient Guideline.
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Acceptability and feasibility
The acceptability of each frailty instrument to clinicians
and patients will be assessed using Likert scale scored
questions based on relevant queries from previously vali-
dated acceptability scales [46]. We will recruit a conveni-
ence sample of 30 clinicians in the preoperative
assessment unit who are willing to administer each
frailty instrument in the clinical assessment of a partici-
pating patient. All patient participants will be asked to
assess the acceptability of each tool and the full data col-
lection process. Feasibility will be assessed in the domain
of practicality, based on presence and frequency of miss-
ing items and time of administration [47]. Feasibility and
acceptability scales are included in the Appendix.
Descriptive analysis
Patient and clinical characteristics will be compared
across frail and non-frail strata using descriptive
statistics.
Primary analysis
Our primary analysis will calculate the predictive accur-
acy of each of the CFS and the mFI in identifying pa-
tients who develop a new disability or die in the 90 days
after surgery using concepts from diagnostic accuracy
testing. Specifically, we will compare the true positive
rate (i.e., sensitivity), as well as the false positive rate
(i.e., 1-specificity) between instruments. The true posi-
tive rate reflects the benefit of screening for adverse out-
come risk using a particular instrument by quantifying
the proportion of people who will actually experience
the adverse outcome and who are identified by the in-
strument. Alternatively, the false positive rate reflects
the disadvantage of using the instrument by quantifying
the proportion of people who are erroneously identified
as likely to experience an adverse outcome [48]. We will
use the standard dichotomization of each tool as the test
positive definition for each instrument.
To compare the accuracy of the two frailty instru-
ments head to head we will use the relative true positive
rate (rTPR), and relative false positive rate (rFPR) with
95% confidence intervals [48]. The rTPR can be inter-
preted as the relative difference in the probability of one
instrument identifying a true case of death or new dis-
ability (i.e., a true positive) compared to another instru-
ment. For example, a rTPR of 1.2 would be interpreted
as the CFS identifying 20% more cases of death or new
disability than the mFI. The A rFPR of 3.0 would be
interpreted as one test incorrectly identifying 3 times
more people as likely to experience death or new disabil-
ity. A rTPR or rFPR with a confidence interval excluding
the null value (i.e., 1) will be considered to indicate a sig-
nificant difference in accuracy between frailty instru-
ments. Because different clinical scenarios may call for
an instrument with higher sensitivity, while others may
require higher specificity, the preferred instrument will
ultimately be determined by the indication for its use.
However, if one instrument is found to have a signifi-
cantly higher true positive rate and a significantly lower
false positive rate it would likely be superior in most
settings.
We will also perform subgroup analyses in pertinent
procedural cohorts, including total joint arthroplasty,
intra-abdominal surgery, oncology, and vascular surgery.
In each subgroup, a separate rTPR, rFPR and associated
95% CIs will be calculated.
Secondary analyses
In addition to the dichotomized definition of frailty used
in our primary analysis, both the mFI and CFS provide
an ordinal frailty scale. Therefore, to assess the discrim-
inatory performance of each frailty scale expressed on an
ordinal basis, we will perform a receiver operator char-
acteristic (ROC) curve analysis to identify whether a dif-
ferent optimal cut-point may exist for each frailty
instrument in the perioperative setting [49]. If a cut-
point is identified that is different than those typically
used, we will repeat our rTPR analysis using the newly
identified cut point.
We will also measure the strength of association be-
tween frailty and primary and secondary study outcomes
using regression coefficients and 95% confidence inter-
vals from an appropriate model: for dichotomous out-
comes we will calculate the odds ratio using logistic
regression, for length of stay (time to discharge) we will
calculate the hazard ratio using Cox proportional haz-
ards regression, for hospital and health system costs we
will use relative difference from generalized linear
regression.
Exploratory analysis
In addition to frailty, the ACS/AGS Optimal Pre-
operative Assessment of the Geriatric Surgical Patient
recommends assessment of a variety of patient condi-
tions and characteristics [23]. Therefore, to explore
the contribution of other variables to predicting death
or new disability in our cohort of elderly patients, we
will perform exploratory multivariable modelling by
entering all clinically important preoperative covari-
ates together with frailty status into a logistic regres-
sion model and using a backward elimination
algorithm to produce a parsimonious model that can
predict the occurrence of new death or disability. The
discrimination of the model will be assessed using
area under the ROC curve (C-statistic) with 95% con-
fidence interval, and calibration will be assessed using
the Hosmer-Lemeshow goodness of fit test.
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Assessment of acceptability and feasibility
We will measure the acceptability of each instrument for
clinicians by reporting the mean and standard deviation
of each acceptability question for each tool, as well as an
aggregate mean and standard deviation across questions.
For patients, we will calculate the mean and standard
deviation for each instrument in relation to the per-
ceived of ease of use, and whether the patient would be
willing to complete the instrument again in the future.
We will measure the feasibility of each instrument by
expressing the mean number of missing items from each
frailty instrument. We will also calculate the mean time
in seconds that were required to complete each
instrument.
Sample size
The sample size calculation is based on the primary ob-
jective of comparing the mFI (≥3) and CFS (≥4) with re-
spect to their accuracy in identifying patients with
events at 90 days after surgery. We used the sample size
calculation approach described by Alonzo et al. for
paired comparisons of diagnostic test accuracy [48]. The
approach is based on the joint 95% confidence region
around the relative True Positive Rate (rTPR) and False
Positive Rates (rFPR), but since prevalence of events is
expected to be low, the sample size is driven entirely by
the calculation for rTPR. Although no measures of sen-
sitivity for detecting true cases of DFS are available for
the CFS or mFI, existing literature suggests that the mFI
has a 61% sensitivity for identifying true cases of postop-
erative complications [16]. Therefore, we assumed a TPR
for the mFI as a sensitivity of 0.6. We would consider a
30% relative difference in the TPR for the CFS to be
clinically meaningful. We further assumed a concord-
ance probability (i.e., the proportion of patients classified
as positive by both tests, of 0.45). To have 80% power at
a 5% significance level to detect a rTPR of 1.3, the re-
quired number of cases is 117. At a prevalence of events
of 18%, this translates to a total required sample size for
the cohort of 648 patients.
Discussion
This multicenter prospective cohort study will address
multiple knowledge gaps in the perioperative frailty evi-
dence base. We will describe the comparative perform-
ance of two leading frailty instruments in predicting a
patient reported outcome measure (DFS), as well as
commonly reported postoperative outcomes. Further-
more, we will assess the predictive value of two frailty
instruments in addition to known preoperative risk fac-
tors. Finally, we will provide new information regarding
the acceptability and feasibility of the mFI and CFS,
which in addition to their predictive accuracy, should
guide clinicians in choosing an appropriate instrument
with which to perform preoperative frailty assessments.
Given the rapid aging of Western populations [50, 51],
and the increasing prevalence of older patients in the
perioperative setting [7], accurate and routine identifica-
tion of the high risk strata of frail older patients is
needed to inform patient and surgical decision making,
and to appropriately plan perioperative care. The pleth-
ora of available frailty instruments combined with a lack
of comparative studies creates a substantial barrier for
uptake of frailty instruments by clinicians [52], despite
such assessments being recommended by best practice
guidelines [23, 24]. Furthermore, the association of avail-
able frailty instruments with patient reported outcome
measures, which have recently been identified as key
areas for new research [53], is poorly studied. This lack
of data may cloud the interpretation of frailty status be-
fore surgery for patients and clinicians. Our study will
provide important insights into each of these needed
areas of research.
Feasibility and acceptability are known external bar-
riers to practice change [54]. Although some evidence
exists regarding the feasibility of the mFI in periopera-
tive practice and the CFS in non-surgical settings, the
comparative feasibility and acceptability of different
frailty instruments is not well described. Our study will
supplement measures of comparative diagnostic accur-
acy between the CFS and mFI with acceptability and
feasibility measures based on accepted frameworks. The
combination of these data should influence the future
practice of frailty assessments and the application of best
practice guidelines.
Appendix
Measures of feasibility and acceptability
Acceptability
For clinicians: Was the frailty instrument… (1 being least
easy/5 being most easy)
1. Easy to use? (1-2-3-4-5)
2. Useful in my practice? (1-2-3-4-5)
3. Beneficial to patients care? (1-2-3-4-5)
4. Miss important clinical factors? (1-2-3-4-5)
5. Difficult to use for environmental/logistical
reasons? (1-2-3-4-5)
For patients: Was this questionnaire (or group of
questionnaires)… (1 being least easy/5 being most easy)
1. Easy to use? (1-2-3-4-5)
2. Something you would be willing to do again if it
helped your future care? (1-2-3-4-5)
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Feasibility
For each tool (mFI/CFS/Optimal Preoperative Assess-
ment guideline) we will measure:
1. Time to administer
2. Number of missing items (based on typical practice
for lab tests and diagnostics-no extra lab tests will
be ordered as part of this study protocol)
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